June brought major blood cancer updates, and CURE is sharing the latest in myelofibrosis treatment and FDA breakthroughs, as ...

Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry ...

Incyte INCY announced that the FDA has extended the review period for the supplemental new drug application (sNDA) for ...

Non-JAK2 mutations, particularly in SRSF2, ASXL1, and IDH2, were independently associated with worse survival outcomes in ...

Israel launches strikes on missile facilities in central Iran: air force Incyte (Nasdaq:INCY) today announced the first clinical data from two studies evaluating the safety, tolerability and efficacy ...

DataM Intelligence | competitive Intelligence JAK combos, epigenetic drugs, & non-JAK agents are redefining myelofibrosis treatment offerin ...

Panelists discuss how to select among the four available JAK inhibitors (Ruxolitinib, Fedratinib, Pacritinib, and Momelotinib) based on patient-specific factors such as anemia, thrombocytopenia, and ...

During a live event, Mojtaba Akhtari, MD, discussed the goals and treatment approach for patients with low-risk polycythemia ...

Silence Therapeutics presents additional data from phase 1 study of divesiran as potential first-in-class siRNA treatment for polycythemia vera: London Monday, June 16, 2025, 18:0 ...

Disc Medicine, Inc. (NASDAQ:IRON) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 11, ...

Positive updates across all programs, including longer term efficacy and safety data from the HELIOS open-label extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional ...

Polycythemia vera and myelofibrosis. Myelofibrosis is a type of blood cancer that's very similar to the end stages of polycythemia vera. It happens because too many abnormal cells break down in ...